Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
<p><strong>Background</strong> The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to es...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2022
|
| _version_ | 1826309725399023616 |
|---|---|
| author | Butler, CC Hobbs, FDR Gbinigie, OA Rahman, NM Hayward, G Richards, DB Dorward, J Lowe, DM Standing, JF Breuer, J Khoo, S Petrou, S Hood, K Nguyen-Van-Tam, JS Patel, MG Saville, BR Marion, J Ogburn, E Allen, J Rutter, H Francis, N Thomas, NPB Evans, P Dobson, M Madden, T-A Holmes, J Harris, V Png, ME Lown, M van Hecke, O Detry, MA Saunders, CT Fitzgerald, M Berry, NS Mwandigha, L Galal, U Mort, S Jani, BD Hart, ND Ahmed, H Butler, D McKenna, M Chalk, J Lavallee, L Hadley, E Cureton, L Benysek, M Andersson, M Coates, M Barrett, S Bateman, C Davies, JC Raymundo-Wood, I Ustianowski, A Carson-Stevens, A Yu, L-M Little, P |
| author2 | PANORAMIC Trial Collaborative Group |
| author_facet | PANORAMIC Trial Collaborative Group Butler, CC Hobbs, FDR Gbinigie, OA Rahman, NM Hayward, G Richards, DB Dorward, J Lowe, DM Standing, JF Breuer, J Khoo, S Petrou, S Hood, K Nguyen-Van-Tam, JS Patel, MG Saville, BR Marion, J Ogburn, E Allen, J Rutter, H Francis, N Thomas, NPB Evans, P Dobson, M Madden, T-A Holmes, J Harris, V Png, ME Lown, M van Hecke, O Detry, MA Saunders, CT Fitzgerald, M Berry, NS Mwandigha, L Galal, U Mort, S Jani, BD Hart, ND Ahmed, H Butler, D McKenna, M Chalk, J Lavallee, L Hadley, E Cureton, L Benysek, M Andersson, M Coates, M Barrett, S Bateman, C Davies, JC Raymundo-Wood, I Ustianowski, A Carson-Stevens, A Yu, L-M Little, P |
| author_sort | Butler, CC |
| collection | OXFORD |
| description | <p><strong>Background</strong>
The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population.</p>
<p><strong>Methods</strong>
PANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older—or aged 18 years or older with relevant comorbidities—and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive 800 mg molnupiravir twice daily for 5 days plus usual care or usual care only. A secure, web-based system (Spinnaker) was used for randomisation, which was stratified by age (<50 years <i>vs</i> ≥50 years) and vaccination status (yes <i>vs</i> no). COVID-19 outcomes were tracked via a self-completed online daily diary for 28 days after randomisation. The primary outcome was all-cause hospitalisation or death within 28 days of randomisation, which was analysed using Bayesian models in all eligible participants who were randomly assigned. This trial is registered with ISRCTN, number 30448031.</p>
<p><strong>Findings</strong>
Between Dec 8, 2021, and April 27, 2022, 26 411 participants were randomly assigned, 12 821 to molnupiravir plus usual care, 12 962 to usual care alone, and 628 to other treatment groups (which will be reported separately). 12 529 participants from the molnupiravir plus usual care group, and 12 525 from the usual care group were included in the primary analysis population. The mean age of the population was 56·6 years (SD 12·6), and 24 290 (94%) of 25 708 participants had had at least three doses of a SARS-CoV-2 vaccine. Hospitalisations or deaths were recorded in 105 (1%) of 12 529 participants in the molnupiravir plus usual care group versus 98 (1%) of 12 525 in the usual care group (adjusted odds ratio 1·06 [95% Bayesian credible interval 0·81–1·41]; probability of superiority 0·33). There was no evidence of treatment interaction between subgroups. Serious adverse events were recorded for 50 (0·4%) of 12 774 participants in the molnupiravir plus usual care group and for 45 (0·3%) of 12 934 in the usual care group. None of these events were judged to be related to molnupiravir.</p>
<p><strong>Interpretation</strong>
Molnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community.</p>
<p><strong>Funding</strong>
UK National Institute for Health and Care Research</p> |
| first_indexed | 2024-03-07T07:40:00Z |
| format | Journal article |
| id | oxford-uuid:d4c98b57-bbce-4622-8b61-b00b6a9e1916 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:40:00Z |
| publishDate | 2022 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:d4c98b57-bbce-4622-8b61-b00b6a9e19162023-04-12T15:19:31ZMolnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d4c98b57-bbce-4622-8b61-b00b6a9e1916EnglishSymplectic ElementsElsevier2022Butler, CCHobbs, FDRGbinigie, OARahman, NMHayward, GRichards, DBDorward, JLowe, DMStanding, JFBreuer, JKhoo, SPetrou, SHood, KNguyen-Van-Tam, JSPatel, MGSaville, BRMarion, JOgburn, EAllen, JRutter, HFrancis, NThomas, NPBEvans, PDobson, MMadden, T-AHolmes, JHarris, VPng, MELown, Mvan Hecke, ODetry, MASaunders, CTFitzgerald, MBerry, NSMwandigha, LGalal, UMort, SJani, BDHart, NDAhmed, HButler, DMcKenna, MChalk, JLavallee, LHadley, ECureton, LBenysek, MAndersson, MCoates, MBarrett, SBateman, CDavies, JCRaymundo-Wood, IUstianowski, ACarson-Stevens, AYu, L-MLittle, PPANORAMIC Trial Collaborative Group<p><strong>Background</strong> The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population.</p> <p><strong>Methods</strong> PANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older—or aged 18 years or older with relevant comorbidities—and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive 800 mg molnupiravir twice daily for 5 days plus usual care or usual care only. A secure, web-based system (Spinnaker) was used for randomisation, which was stratified by age (<50 years <i>vs</i> ≥50 years) and vaccination status (yes <i>vs</i> no). COVID-19 outcomes were tracked via a self-completed online daily diary for 28 days after randomisation. The primary outcome was all-cause hospitalisation or death within 28 days of randomisation, which was analysed using Bayesian models in all eligible participants who were randomly assigned. This trial is registered with ISRCTN, number 30448031.</p> <p><strong>Findings</strong> Between Dec 8, 2021, and April 27, 2022, 26 411 participants were randomly assigned, 12 821 to molnupiravir plus usual care, 12 962 to usual care alone, and 628 to other treatment groups (which will be reported separately). 12 529 participants from the molnupiravir plus usual care group, and 12 525 from the usual care group were included in the primary analysis population. The mean age of the population was 56·6 years (SD 12·6), and 24 290 (94%) of 25 708 participants had had at least three doses of a SARS-CoV-2 vaccine. Hospitalisations or deaths were recorded in 105 (1%) of 12 529 participants in the molnupiravir plus usual care group versus 98 (1%) of 12 525 in the usual care group (adjusted odds ratio 1·06 [95% Bayesian credible interval 0·81–1·41]; probability of superiority 0·33). There was no evidence of treatment interaction between subgroups. Serious adverse events were recorded for 50 (0·4%) of 12 774 participants in the molnupiravir plus usual care group and for 45 (0·3%) of 12 934 in the usual care group. None of these events were judged to be related to molnupiravir.</p> <p><strong>Interpretation</strong> Molnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community.</p> <p><strong>Funding</strong> UK National Institute for Health and Care Research</p> |
| spellingShingle | Butler, CC Hobbs, FDR Gbinigie, OA Rahman, NM Hayward, G Richards, DB Dorward, J Lowe, DM Standing, JF Breuer, J Khoo, S Petrou, S Hood, K Nguyen-Van-Tam, JS Patel, MG Saville, BR Marion, J Ogburn, E Allen, J Rutter, H Francis, N Thomas, NPB Evans, P Dobson, M Madden, T-A Holmes, J Harris, V Png, ME Lown, M van Hecke, O Detry, MA Saunders, CT Fitzgerald, M Berry, NS Mwandigha, L Galal, U Mort, S Jani, BD Hart, ND Ahmed, H Butler, D McKenna, M Chalk, J Lavallee, L Hadley, E Cureton, L Benysek, M Andersson, M Coates, M Barrett, S Bateman, C Davies, JC Raymundo-Wood, I Ustianowski, A Carson-Stevens, A Yu, L-M Little, P Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial |
| title | Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial |
| title_full | Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial |
| title_fullStr | Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial |
| title_full_unstemmed | Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial |
| title_short | Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial |
| title_sort | molnupiravir plus usual care versus usual care alone as early treatment for adults with covid 19 at increased risk of adverse outcomes panoramic an open label platform adaptive randomised controlled trial |
| work_keys_str_mv | AT butlercc molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT hobbsfdr molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT gbinigieoa molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT rahmannm molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT haywardg molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT richardsdb molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT dorwardj molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT lowedm molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT standingjf molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT breuerj molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT khoos molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT petrous molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT hoodk molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT nguyenvantamjs molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT patelmg molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT savillebr molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT marionj molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT ogburne molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT allenj molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT rutterh molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT francisn molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT thomasnpb molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT evansp molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT dobsonm molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT maddenta molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT holmesj molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT harrisv molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT pngme molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT lownm molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT vanheckeo molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT detryma molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT saundersct molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT fitzgeraldm molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT berryns molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT mwandighal molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT galalu molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT morts molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT janibd molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT hartnd molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT ahmedh molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT butlerd molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT mckennam molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT chalkj molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT lavalleel molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT hadleye molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT curetonl molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT benysekm molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT anderssonm molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT coatesm molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT barretts molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT batemanc molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT daviesjc molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT raymundowoodi molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT ustianowskia molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT carsonstevensa molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT yulm molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial AT littlep molnupiravirplususualcareversususualcarealoneasearlytreatmentforadultswithcovid19atincreasedriskofadverseoutcomespanoramicanopenlabelplatformadaptiverandomisedcontrolledtrial |